Skip to main content

Table 1 Patients’ characteristics

From: Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

  

Oral vinorelbine dose arms

  

30 mg

40 mg

50 mg

Patients

N

27

24

22

Age

median

67

66

67

 

range

43-74

48-75

44-75

Gender

Male

18 (66.6%)

17 (70.8%)

15 (68.2%)

 

Female

9 (33.4%)

7 (29.2%)

7 (31.8)

Cancer type

Breast

7 (26.0%)

6 (25.0%)

7 (31.8%)

 

Prostate

8 (29.6%)

7 (29.2%)

7 (31.8%)

 

NSCLC

12 (44.4%)

11 (45.8%)

8 (36.4%)

PS

0

8 (29.6%)

10 (41.6%)

8 (36.4%)

 

1

15 (55.6%)

11 (45.8%)

12 (54.6%)

 

2

4 (14.8%)

3 (12.6%)

2 (9.0%)

Prior chemotherapy

0

5 (18.6%)

4 (16.6%)

5 (22.8%)

 

1

13 (48.2%)

12 (50.0%)

11 (50.0%)

 

2

9 (33.4%)

8 (33.4%)

6 (27.2%)

Prior radiotherapy

 

14 (51.8%)

8 (33.4%)

11 (50.0%)

Prior hormonotherapy

 

12 (44.4%)

11 (44.8%)

13 (59.0%)

Organs with metastases

lung

15 (55.6%)

14 (58.4%)

10 (45.4%)

 

liver

8 (29.6%)

4 (16.6%)

3 (13.6%)

 

bone

18 (66.6%)

15 (62.6%)

9 (41%)